Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 122, Issue 6, 2015, Pages 785-794

  Cassone, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Candida albicans; immunity; pathogenesis; vaccines; vulvovaginal candidiasis

Indexed keywords

ASPARTIC PROTEINASE; CANDIDA ALBICANS VACCINE; FUNGUS VACCINE;

CANDIDA ALBICANS; DRUG INDICATION; FUNGAL VIRULENCE; FUNGUS HYPHAE; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; VAGINA CANDIDIASIS; VAGINA FLORA; YEAST; CANDIDIASIS, VULVOVAGINAL; FEMALE; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY;

CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; FEMALE; FUNGAL VACCINES; HUMANS; RECURRENCE;

EID: 84928046816     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12994     Document Type: Review

References (83)

1. Eckert LO,. Acute vulvovaginitis. N Engl J Med 2006; 355: 1244-52.
2. Moreira D, Paula CR,. Vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92: 266-7.
3. Ringdahl EN,. Recurrent vulvovaginal candidiasis. Mol Med 2006; 103: 165-8.
4. Sobel JD,. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14: S148-53.
5. Bauters TG, Dhont MA, Temmerman MI, Nelis JH,. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569-74.
6. Borges S, Silva J, Teixeira P,. The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet 2014; 289: 479-89.
7. Sobel JD, Wiesenfield HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351: 876-83.
8. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J,. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 2013; 17: 340-5.
9. Mardh PA, Wagstrom J, Landgren M, Holmen J,. Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analysis of a unique database. Infect Dis Obstet Gynecol 2004; 12: 91-7.
10. Puel A, Cypowyj S, Marõdi L, Abel L, Picard C, Casanova JL,. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12: 616-22.
11. Babula O, Lazdane G, Kroicka J, Ledger WJ, Witkin SS,. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37: 733-7.
12. Babula O, Lazdane G, Kroicka J, Linhares IM, Ledger WJ, Witkin SS,. Frequency of Interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40: 1258-62.
13. Smeekens SP, van de Veerdonk FL, Kullberg BJ, Netea MG,. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5: 805-13.
14. Liu F, Liao Q, Liu Z,. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92: 43-7.
15. De Luca A, Carvalho A, Cunha C, Iannitti RG, Pitzurra L, Giovannini G, et al. IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog 2013; 9: e1003486.
16. Wang Y,. CDKs and the yeast-hyphal decision. Curr Opin Microbiol 2009; 12: 644-9.
17. Chandra J, Khun DM, Mukherjiee PK, Hoyer LL, McCormick T, Ghannoum MA,. Biofilm formation by the fungal pathogen Candida albicans: development, architecture and drug resistance. J Bacteriol 2001; 183: 5385-94.
18. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL Jr, Noverr MC,. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 2010; 156: 3635-44.
19. Lo H, Kholer JR, Di Domenico B, Loebenberg D, Cacciapuoti A, Fink GR,. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-49.
20. Peters BM, Palmer GE, Nash AK, Lilly EA, Fidel PL Jr, Noverr MC,. Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. Infect Immun 2014; 82: 532-43.
21. Neves NA, Carvalho LP, De Oliveira MA, Giraldo PC, Bacellar O, Cruz AA, et al. Association between atopy and recurrent vaginal candidiasis. Clin Exp Immunol 2005; 142: 167-71.
22. Ildgruben AK, Sjoberg IM, Hammarstrom MLKC,. Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol 2003; 102: 571-82.
23. Kinsman OS, Collard AE,. Hormonal factors in vaginal candidiasis in rats. Infect Immun 1986; 53: 498-504.
24. Spacek JV, Buchta M, Jilek P, Forstl M,. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 2006; 131: 198-202.
25. Cassone A, De Bernardis F, Santoni G,. Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Infect Immun 2007; 75: 4675-86.
26. Black CA, Eyers FM, Russell A, Dunkley ML, Clancy RL, Beagley KV,. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 1998; 66: 1273-5.
27. Fidel PL, Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004; 72: 2939-46.
28. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F,. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal re-infection. Infect Immun 1995; 63: 2619-24.
29. Fidel PL Jr, Lynch ME, Conaway DH, Tait L, Sobel JD,. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun 1995; 63: 547-53.
30. Cassone A,. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol 2013; 11: 884-91.
31. Alangaden GJ,. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am 2011; 25: 201-25.
32. De Bernardis F, Sullivan PA, Cassone A,. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 2001; 39: 303-13.
33. Naglick JR, Challacombe S, Hube B,. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 43: 73-7.
34. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L,. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156: 777-83.
35. De Bernardis F, Agatensi L, Ross IK, Emerson GW, Lorenzini R, Sullivan PA, et al. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J Infect Dis 1990; 161: 1276-83.
36. De Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schäfer W, et al. Evidence that members of the secretory aspartyl proteinase gene family, in particular Sap2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201-8.
37. Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M, et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun 2003; 71: 3227-34.
38. Schaller M, Korting HC, Borelli C, Hamm G, Hube B,. Candida albicans secreted aspartic: proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. Infect Immun 2005; 73: 2758-65.
39. Pietrella D, Pandey N, Gabrielli E, Pericolini E, Perito S, Kasper L, et al. Secreted aspartic proteases of Candida albicans activate the NLRP3 inflammasome. Eur J Immunol 2013; 43: 679-92.
40. Naglick JR, Rodgers CA, Shirlaw PJ, Dobbie JL, Fernandes-Naglik LL, Greenspan D, et al. Differential expression of Candida albicans proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469-79.
41. Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 2008; 154: 3266-80.
42. Villar CC, Kashleva H, Nobile CJ, Mitchell AP, Dongari-Bagtzoglou A,. Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation, mediated by transcription factor Rim101p and protease Sap5. Infect Immun 2007; 75: 2126-35.
43. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A,. Protective role of antimannan and anti-aspartyl proteinase Abs in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997; 65: 3399-405.
44. De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 2012; 30: 4490-8.
45. Cole AM,. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006; 306: 199-230.
46. Elitsur Y, Jackman S, Neace C, Keerthy S, Liu X, Dosescu J, et al. Human vaginal mucosa immune system: characterization and function. Gen Diagn Pathol 1998; 143: 271-7.
47. Fidel PL Jr,. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 2007; 57: 2-12.
48. + T cells in protection against vaginal candidosis. Clin Exp Immunol 2003; 131: 26-33.
49. Pellis V, De Seta F, Crovella S, Bossi F, Bulla R, Guaschino S, et al. Type I T helper cells specific for Candida albicans Ags in peripheral blood and vaginal mucosa of women with recurrent vaginal candidiasis. J Infect Dis 2002; 186: 87-93.
50. Wira CR, Fahey JV, Stentman CL, Pioli PA, Shen L,. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206: 303-53.
51. Wira CR, Grant-Tschudy KS, Crane-Goudreau MA,. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am J Reprod Immunol 2005; 53: 65-76.
52. Witkin SS,. Immunology of the vagina. Clin Obstet Gynecol 1993; 36: 122-8.
53. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F, et al. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS ONE 2011; 6: e22770.
54. Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA, Brown GD, et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009; 5: 487-97.
55. Huppler AR, Conti HR, Hernández-Santos N, Darville T, Biswas PS, Gaffen SL,. Role of neutrophils in il-17-dependent immunity to mucosal candidiasis. J Immunol 2014; 192: 1745-52.
56. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5: e1000703.
57. Czerkinnsky C, Anjuere F, McGhee JR, George-Chandy A, Holmgren J, Kieny MP, et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999; 170: 197-222.
58. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695-706.
59. Romani L, Puccetti P,. Protective tolerance to fungi. The role of IL-10 and tryptophan metabolism. Trends Microbiol 2006; 14: 183-9.
60. Sansonetti PJ,. Microbiota and the immune system, an amazing mutualism forged by co-evolution. Semin Immunol 2013; 25: 321-2.
61. Moyes DL, Murciano C, Runglall M, Islam A, Thavaraj S, Naglik JR,. Candida albicans yeast and hyphae are discriminated by MAPK signaling in vaginal epithelial cells. PLoS ONE 2011; 6: e26580.
62. Eloe-Fadrosh EA, Rasko DA,. The human microbiome: from symbiosis to pathogenesis. Annu Rev Med 2013; 64: 145-63.
63. Pirotta M, Gunn J, Chondros P, Grover S, Hurley S, Garland S,. The PAV trial: does lactobacillus prevent post-antibiotic vulvovaginal candidiasis? Protocol of a randomised controlled trial [ISRCTN24141277]. BMC Fam Pract 2004; 5: 5.
64. O'Hanlon DE, Moench TR, Cone RA,. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS ONE 2013; 8: e80074.
65. Vylkova S, Carman AJ, Danhof HA, Collette JR, Zhou H, Lorenz MC,. The fungal pathogen Candida albicans autoinduces hyphal morphogenesis by raising extracellular pH. MBio 2011; 2: e00055-11.
66. Mossop H, Linhares IM, Bongiovanni AM, Ledger WJ, Witkin SS,. Influence of lactic acid on endogenous and viral RNA-induced immune mediator production by vaginal epithelial cells. Obstet Gynecol 2011; 118: 840-6.
67. Zhou X, Westman R, Hickey R, Hansmann MA, Kennedy C, Osborn TW, et al. Vaginal microbiota of women with frequent vulvovaginal candidiasis. Infect Immun 2009; 77: 4130-5.
68. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39: 372-85.
69. Liu MB, Xu SR, He Y, Deng GH, Sheng HF, Huang XM, et al. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS ONE 2013; 8: e79812.
70. Ene IV, Cheng SC, Netea MG, Brown AJ,. Growth of Candida albicans cells on the physiologically relevant carbon source lactate affects their recognition and phagocytosis by immune cells. Infect Immun 2013; 81: 238-48.
71. Ostrowski-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH,. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9: 719-27.
72. Magliani W, Conti S, De Bernardis F, Cassone A, Polonelli L,. New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002; 8: 121-6.
73. Cutler JE, Deepe GS, Klein D,. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5: 13-28.
74. Cassone A,. Fungal vaccines: real progress from real challenge. Lancet Infect Dis 2008; 8: 114-24.
75. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012; 30: 7594-600.
76. Saville SP, Lazzell AJ, Chaturvedi A, Monteagudo C, Lopez-Ribot JL,. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hemathogeneously disseminated candidiasis. Clin Vaccine Immunol 2009; 16: 430-2.
77. Xin H, Dziadek S, Bundle DR, Cutler JE,. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 2008; 105: 13526-31.
78. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3-glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 2009; 4: e5392.
79. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X,. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A 2011; 108: 4388-93.
80. Wagner RD, Johnson SJ,. Probiotic lactobacillus and estrogen effects on vaginal epithelial gene expression responses to Candida albicans. J Biomed Sci 2012; 19: 58.
81. Relloso M, Aragoneses-Fenoll L, Lasarte S, Bourgeois C, Romera G, Kuchler K, et al. Estradiol impairs the Th17 immune response against Candida albicans. J Leukoc Biol 2012; 91: 159-65.
82. Zhang X, Essmann M, Burt ET, Larsen B,. Estrogen effects on Candida albicans: a potential virulence-regulating mechanism. J Infect Dis 2000; 181: 1441-6.
83. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y,. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 2006; 97: 1198-204.